Mutants of trichosanthin with anti-tumor activity and lowered side-effects
US7763581B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Inventors
Key dates
| Filing date | Aug 4, 2005 |
| Grant date | Jul 27, 2010 |
| Priority date | — |
| Expiry date | Dec 12, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides the mutants and coding genes of trichosanthin (TCS). The mutants thereof are the TCS mutants with the single or double alternation of tyrosine-55 and aspartate-78 (counted from N-terminus), wherein the tyrosine-55 is mutated to an aliphatic amino acid and aspartate-78 is mutated to an amino acid with low hydrophilicity. This invention also relates to the application of TCS mutants and their coding genes in the drug development to treat carcinoma, AIDS and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.